1478800
USP
奥利司他
United States Pharmacopeia (USP) Reference Standard
别名:
N-甲酰基-L-亮氨酸（1S）-1 - [[（2S，3S）-3-己基-4-氧代-2-氧杂环丁烷基]甲基]十二烷基酯, Ro-18-0647, （−）-四氢脂抑素
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C29H53NO5
CAS Number:
分子量:
495.73
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
orlistat
制造商/商品名称
USP
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O
InChI
1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1
InChI key
AHLBNYSZXLDEJQ-FWEHEUNISA-N
基因信息
human ... LIPF(8513), PNLIP(5406)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
生化/生理作用
奥利司他用于肥胖症研究，是一种胰脂肪酶抑制剂，在胃肠道局部起作用以抑制脂肪酶。
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
溶液不完全澄清，小颗粒可能仍然悬浮。
Sales restrictions may apply.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Peter Hertzman
PharmacoEconomics, 23(10), 1007-1020 (2005-10-21)
To calculate the cost effectiveness (from the Swedish healthcare perspective) of orlistat plus diet for an obese and overweight population in a 1-year weight-management responder programme versus a 1-year weight-management programme based on diet only. As a reference, orlistat plus
K Johansson et al.
Obesity reviews : an official journal of the International Association for the Study of Obesity, 11(11), 777-791 (2009-12-23)
Previous meta-analyses investigating blood pressure effects of anti-obesity drugs have included studies using non-licensed doses, but not data from head-to-head studies. Furthermore, although diabetes is an important comorbidity in obesity, variation in blood pressure effects across diabetes status has not
Monique P Curran et al.
Treatments in endocrinology, 4(2), 127-129 (2005-03-24)
Orlistat is an inhibitor of gastrointestinal lipases and, therefore, prevents the absorption of dietary fat. This agent reduced weight in obese adults and adolescents with or without co-morbidities (including type 2 diabetes mellitus, hypercholesterolemia, hypertension, metabolic syndrome) who received up
Katie S McClendon et al.
Expert opinion on drug safety, 8(6), 727-744 (2009-12-10)
Obesity has rapidly become a life-threatening epidemic worldwide. There are a plethora of obesity-related co-morbidities and complications that increase morbidity, mortality and cost of care associated with obesity. Orlistat is approved for the treatment of obesity and has been evaluated
Miguel A Rubio et al.
Public health nutrition, 10(10A), 1200-1205 (2007-11-21)
Modification of lifestyle is the main therapeutical approach in the treatment of obesity, but use to fail on long terms of time. Addition of anti-obesity drugs allows keeping the weight loss during years and improving obesity-related comorbidities. This review is
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持